DARE: Drug-Coated Balloons Compete with DES for the Treatment of In-Stent Restenosis

Courtesy of the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI).

The SeQuent Please paclitaxel-coated balloon provides non-inferior angiographic results when compared with the Xience everolimus-eluting stent for the treatment of in-stent restenosis.

DARE: los balones farmacológicos compiten con los DES para tratar la reestenosis intrastent

At 6 months, the minimal lumen diameter was 1.71 mm in the drug-coated balloon arm and 1.74 mm in the Xience arm, a difference that met criteria for non-inferiority (p < 0.0001). There were no differences in clinical endpoints, although the study did not have enough statistical for those endpoints.


Read also: Fentanyl in Angioplasty: What Is the Price of More Comfort During the Procedure?”


These findings were published simultaneously in the JACC: Cardiovascular Interventions and are concordant with current European guidelines, which provide class IA recommendations for both drug-eluting stents (DES) and drug-coated balloons for the treatment of in-stent restenosis within bare-metal stents (BMS) or DES.

 

The DARE study was carried out at 8 Dutch centers and enrolled 278 patients with in-stent restenosis (56% had restenosis in a DES). About 60% of patients presented with acute coronary syndrome.


Read also: MitraClip Procedure Can Be Performed without General Anesthesia”.


DES treatment resulted in a larger minimal lumen diameter and a lower percentage of residual stenosis. Those differences were lost at follow-up by greater late lumen loss in the DES arm (0.45 vs. 0.17 mm; p < 0.001) at the 6-month angiographic follow-up.

 

Courtesy of the SBHCI.

 

Original title: A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of any In-Stent Restenosis: The DARE Trial.

Presenter: José Henriques.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...